ISCO Chairman Kenneth Aldrich to Discuss 'Status of the Company'
International Stem Cell Corporation (OTCBB:ISCO),
a California-based biotechnology company creating human stem cell lines
through its patented parthenogenetic process that requires no use of
fertilized embryos, today announced that it is has scheduled a
conference call for June 15, 2010 at 10:00 a.m. PST. ISCO Chairman, Mr.
Kenneth Aldrich will discuss the Company's newly issued patent, its
recently completed financing, and the present status of the company and
its vision for the coming year. The dial-in number for participants is 1
(800) 774-6070 and the pass code ID is 8273 225#. An alternate dial-in
number is: 1 (630) 691-2753 and the pass code will be the same for both
numbers. A replay of the call will be available on the home page of the
company's web site at: http://www.internationalstemcell.com.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California-based biotechnology
company focused on therapeutic and research products. ISCO's core
technology, parthenogenesis, results in creation of pluripotent human
stem cells (hpSCs) from unfertilized oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenic, homozygous stem
cell line that can be a source of therapeutic cells with minimal immune
rejection after transplantation into hundreds of millions of individuals
of differing sexes, ages and racial groups. This offers the potential to
create the first true stem cell bank, UniStemCellTM, while
avoiding the ethical issue of using fertilized eggs. ISCO also produces
and markets specialized cells and growth media for therapeutic research
worldwide through its subsidiary Lifeline Cell Technology. More
information is available at ISCO's website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated technological developments and
therapeutic applications, and other opportunities for the company and
its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com or Brian
Lundstrom, President 760-640-6383 bl@intlstemcell.com |